Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors
Hodgkin lymphoma is a highly curable malignancy in early and advanced stages. Most patients are diagnosed in their teens or twenties and are expected to live decades beyond their treatment. Therefore, the toxicity of treatment must be balanced with the goal of cure. Thus, treatment has been refined...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-09-01
|
| Series: | Clinical Medicine Insights: Oncology |
| Online Access: | https://doi.org/10.1177/1179554917731072 |
| _version_ | 1818305296110452736 |
|---|---|
| author | Pamela B Allen Leo I Gordon |
| author_facet | Pamela B Allen Leo I Gordon |
| author_sort | Pamela B Allen |
| collection | DOAJ |
| description | Hodgkin lymphoma is a highly curable malignancy in early and advanced stages. Most patients are diagnosed in their teens or twenties and are expected to live decades beyond their treatment. Therefore, the toxicity of treatment must be balanced with the goal of cure. Thus, treatment has been refined through prognostic models and positron emission tomography-computed tomography (PET-CT)-directed therapy. Stratification by prognostic models defines groups of patients with favorable characteristics who may be treated with less intensive therapy upfront, including fewer cycles of chemotherapy, lower doses of radiation, or omission of radiation altogether. Alternatively, high-risk patients may be assigned to a more aggressive initial approach. The modern use of interim PET-CT allows further tailoring of treatment by response. |
| first_indexed | 2024-12-13T06:24:20Z |
| format | Article |
| id | doaj.art-4b8dbb4789da443f81e9c12711928a0b |
| institution | Directory Open Access Journal |
| issn | 1179-5549 |
| language | English |
| last_indexed | 2024-12-13T06:24:20Z |
| publishDate | 2017-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Oncology |
| spelling | doaj.art-4b8dbb4789da443f81e9c12711928a0b2022-12-21T23:56:45ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492017-09-011110.1177/1179554917731072Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic FactorsPamela B AllenLeo I GordonHodgkin lymphoma is a highly curable malignancy in early and advanced stages. Most patients are diagnosed in their teens or twenties and are expected to live decades beyond their treatment. Therefore, the toxicity of treatment must be balanced with the goal of cure. Thus, treatment has been refined through prognostic models and positron emission tomography-computed tomography (PET-CT)-directed therapy. Stratification by prognostic models defines groups of patients with favorable characteristics who may be treated with less intensive therapy upfront, including fewer cycles of chemotherapy, lower doses of radiation, or omission of radiation altogether. Alternatively, high-risk patients may be assigned to a more aggressive initial approach. The modern use of interim PET-CT allows further tailoring of treatment by response.https://doi.org/10.1177/1179554917731072 |
| spellingShingle | Pamela B Allen Leo I Gordon Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors Clinical Medicine Insights: Oncology |
| title | Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors |
| title_full | Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors |
| title_fullStr | Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors |
| title_full_unstemmed | Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors |
| title_short | Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors |
| title_sort | frontline therapy for classical hodgkin lymphoma by stage and prognostic factors |
| url | https://doi.org/10.1177/1179554917731072 |
| work_keys_str_mv | AT pamelaballen frontlinetherapyforclassicalhodgkinlymphomabystageandprognosticfactors AT leoigordon frontlinetherapyforclassicalhodgkinlymphomabystageandprognosticfactors |